

FIRST

Studie opzet & behandeling: FIRST

A randomized, double-blind, phase 3 comparison of Platinum-based therapy with tsr-042 and niraparib Versus standard of care platinum-based therapy as first-line treatment of stage iii or iv nonmucinous epithelial ovarian cancer

Primair eindpunt: PFS

Aantal benodigde patiënten: 720-960 in 1:1:2 ratio gerandomiseerd

Deelnemende centra: UMCU, ErasmusMC, UMCG, AMC

Contactpersoon / website: An Reyners